Oruka Therapeutics price target raised to $78 from $73 at BTIG

BTIG analyst Julian Harrison raised the firm’s price target on Oruka Therapeutics (ORKA) to $78 from $73 and keeps a Buy rating on the shares. The firm is citing the management having pulled forward EVERLAST-A ORKA-001 (anti-IL-23 mAb) Phase 2a 16wk induction data in moderate-to-severe PsO patients to Q2 from the second half of the year following rapid enrollment, highlighting the likely excitement from physicians and patients around ORKA-001’s potential, the analyst tells investors in a research note.